Corrigendum: The Combination of Schisandrol B and Wedelolactone Synergistically Reverses Hepatic Fibrosis via Modulating Multiple Signaling Pathways in Mice.

Graph: FIGURE 5 A combination of SolB and WeD treatment dramatically inhibits hepatic fibrosis and injury in CCL4-induced hepatic fibrosis mice. Keywords: schisandrol B; wedelolactone; hepatic fibrosis; combined pharmacotherapy; TGF- 1/Smads signaling pathway EN schisandrol B wedelolactone hepatic fibrosis combined pharmacotherapy TGF- 1/Smads signaling pathway 1 2 2 10/11/21 20211007 NES 211007 In the original article, there was a mistake in Figure 5 as published. [Extracted from the article]